The Management Team currently consists of the CEO, CFO, CCO, CBO, CQO, Head of Manufacturing and General Counsel.
The Board of Directors appoints the CEO and decides on the CEO’s remuneration and other benefits. The CEO is responsible for managing and controlling the Company’s business and day-to-day operations with the aim of securing significant, sustained increase in the value of the company for its shareholders in line with Nanoform’s strategy.
The CEO prepares matters for decision by the Board of Directors and implements the decisions of the Board. The CEO reports to the Board of Directors.
Edward Hæggström
Edward Hæggström
Born 1969. Finnish citizen. Co-founder of Nanoform, CEO and a member of the Management Team since 2015.
Education: Ph.D. degree in applied physics from the University of Helsinki and a Master of Business Administration degree in innovation management from Helsinki University of Technology.
Experience: Dr. Hæggström has, among others, been a professor at the University of Helsinki and Head of the Electronics Research Laboratory within the Department of Physics. He has previously held the role of visiting professor of physics at Harvard Medical School, visiting scholar (assistant professor) of physics at Stanford University and project leader at the CERN.
Other current positions of trust: Dr. Hæggström is scientific advisor and the Chairman of the Board of Directors of GlucoModicum Oy.
Holdings in the company: 5,409,405 shares and 408,000 stock options, entitling to same amount of shares in the company.
Albert Hæggström
Albert Hæggström
Chief Financial Officer, born 1971. Finnish citizen. CFO and a member of the Management Team since 2018. Member of the Board of Directors since 2015.
Education: Bachelor of Science degree in economics from Hanken School of Economics in Helsinki.
Experience: Mr. Hæggström has more than 20 years’ experience within finance and investing. Prior roles include positions at Alfred Berg, BNP Paribas, Nordea and SEB.
Other current positions of trust: [-]
Holdings in the company: 749,275 shares and 790,000 stock options, entitling to same amount of shares in the company.
Christian Jones
Christian Jones
Chief Commercial Officer, born 1980. British citizen. Chief Commercial Officer and a member of the Management Team since 2018.
Education: Master of Chemistry degree from the University of Leeds. Fellow of the Royal Society of Chemistry.
Experience: Mr. Jones has served as Commercial Director, Innovator Pharma Products and Solutions at Johnson Matthey Plc and was a member of the Senior Leadership Team for the Global Health Sector. Prior to this he was Head of Asia Pacific Sales and member of the Senior Leadership Team at Dr. Reddy’s Global Custom Pharma Solutions business after holding the roles of Associate Director and Manager of Sales and Business Development, Europe. His first commercial role was at Prosonix Ltd, where he led global business development for their proprietary particle engineering technology. Prosonix was later sold to Circassia for £100M.
Other current positions of trust: Mr. Jones serves on the Advisory Board of Pharma Integrates and Bio Integrates Conferences.
Holdings in the company: 384,000 stock options, entitling to same amount of shares in the company.
Antonio Da Silva
Antonio Da Silva
Born 1974. Nationality – Portuguese. Nanoform’s Chief of Business Operations and a member of the Management Team since January 2023.
Education:Degree in Chemistry from Lisbon University, Faculty of Sciences, Master degree in Quality from the University Aberta of Lisbon.
Experience:Antonio da Silva has an extensive background in the CDMO and particle engineering space, having worked for 19 years at Hovione, where he took part in several pharmaceutical product launches. Antonio has been with Nanoform since 2019 when he joined as Director, Quality Control.
Other current positions of trust:[-]
Holdings in the company: 24,500 shares and 278,032 stock options, entitling to same amount of shares in the company.
Johanna Kause
Johanna Kause
Born 1971. Nationality – Finnish. Nanoform’s Chief Quality Officer and a member of the Management Team since September 2023.
Education: Master’s Degree in Pharmacy from the University of Helsinki.
Experience: Johanna Kause has worked in Quality Management in pharma for 25 years. Before joining Nanoform in 2021 she led the Quality, Regulatory and Pharmacovigilance department at Takeda Pharmaceuticals in Finland and the Baltics.
Other current positions of trust: [-]
Holdings in the company: 130,000 stock options, entitling to same amount of shares in the company.
David Rowe
David Rowe
Born 1967. British citizen. Head of Manufacturing and a member of the Management Team since 2019.
Education: Ph.D. degree in Chemistry from the University of Edinburgh.
Experience: Dr. Rowe has 22 years of Managerial and Technical roles at GlaxoSmithKline plc. He was Particle Size Reduction Lead for GlaxoSmithKline where he chaired the global Centre of Excellence forum. He was a SME (Subject Matter Expert) working with the R&D teams in both the USA and Europe for new assets. He also worked with the global manufacturing network at both GSK and third party sites for lifecycle management of the existing commercial assets.
Other current positions of trust: [-]
Holdings in the company: 413,720 stock options, entitling to same amount of shares in the company.
Peter Hänninen
Peter Hänninen
Born 1988. Nationality – Finnish citizen. Nanoform’s General Counsel and member of the Management Team since September 2020.
Education: Master of Law degree from the University of Helsinki.
Experience: Peter Hänninen has previously served as an attorney in private practice with Borenius Attorneys. In this role, he focused on advising clients in technology, data protection, and general corporate law, with a particular focus on the life science and healthtech sectors. He also held the position of Legal Counsel at the University of Helsinki.
Other current positions of trust: Peter Hänninen has been a Secretary of the Board of Directors at Nanoform since 2015.
Holdings in the company: 133,125 shares and 680,000 stock options, entitlement to an equal amount of shares in the company.